Embelin Alleviates Severe Airway Inflammation in OVA-LPS-Induced Rat Model of Allergic Asthma.

Shazalyana AzmanMahendran SekarSuzana WahidinSiew Hua GanJaishree VaijanathappaSrinivisa Reddy BonamMallika AlvalaPei Teng LumVandana ThakurJayesh V BeladiyaAnita A Mehta

Published in: Journal of asthma and allergy (2021)

Overall, our findings indicate that embelin can alleviate severe airway inflammation in OVA-LPS-induced model of allergic asthma occurring by suppression of Th2-mediated immune response. Due to its promising anti-asthmatic effect, it is recommended that embelin should be investigated in clinical trials against asthma. It should also be further explored against COVID-19 or COVID-like diseases due to its ameliorative effects on cytokines and immune cell infiltration.

Keyphrases

lps induced
allergic rhinitis
lung function
inflammatory response
chronic obstructive pulmonary disease
coronavirus disease
sars cov
immune response
clinical trial
early onset
cystic fibrosis
toll like receptor
air pollution
randomized controlled trial
dendritic cells
mass spectrometry
open label
phase ii